Aripiprazole vs Standard of Care for Metabolic Syndrome in Schizophrenia/Bipolar I

Phase 3, randomised, open-label trial of aripiprazole in schizophrenia, schizoaffective disorder and bipolar I disorder (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Levels at 16 weeks and Mean Baseline Fasting Non-HDL Levels at Day 1. Started Apr 2009; status: terminated.